Evidence map›Paper›PMID 38367738›Full record

ArticleThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2024

Macrophage and CD8 T cell discordance are associated with acute lung allograft dysfunction progression.

Daniel R Calabrese, Christina A Ekstrand, Shivaram Yellamilli, Jonathan P Singer, Steven R Hays, Lorriana E Leard, Rupal J Shah, Aida Venado, Nicholas A Kolaitis, Alyssa Perez and 2 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07538336 (Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07538336 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction

TypeinterventionalSponsorUniversity of California, San FranciscoRan2026 to 2028Enrolled40ConditionsLung TransplantArmsEmapalumab, Placebo
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Acute lung allograft dysfunction predicts lung allograft failure: Construct validity of the 2026 International Society for Heart and Lung Transplantation spirometric definition.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2026
    Observational
  3. Article
  4. Article
  5. Persistent and progressive acute lung allograft dysfunction is linked to cell compositional and transcriptional changes in small airways.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2025
    Article
  6. The prognostic value of single and repeated ≥10% FEVThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2025
    Article
  7. Review
  8. Lung allograft dysbiosis associates with immune response and primary graft dysfunction.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Daniel R CalabreseDepartment of Medicine, University of California, San Francisco, California; Medical Service, Veterans Affairs Health Care System, San Francisco, California. Electronic address: daniel.calabrese@ucsf.edu.
Christina A EkstrandDepartment of Pathology, University of California, San Francisco, California.
Shivaram YellamilliDepartment of Pathology, University of California, San Francisco, California.
Jonathan P SingerDepartment of Medicine, University of California, San Francisco, California.
Steven R HaysDepartment of Medicine, University of California, San Francisco, California.
Lorriana E LeardDepartment of Medicine, University of California, San Francisco, California.
Rupal J ShahDepartment of Medicine, University of California, San Francisco, California.
Aida VenadoDepartment of Medicine, University of California, San Francisco, California.
Nicholas A KolaitisDepartment of Medicine, University of California, San Francisco, California.
Alyssa PerezDepartment of Medicine, University of California, San Francisco, California.
Alexis CombesDepartment of Pathology, University of California, San Francisco, California.
John R GreenlandDepartment of Medicine, University of California, San Francisco, California; Medical Service, Veterans Affairs Health Care System, San Francisco, California.
University of California, San Francisco · USSan Francisco VA Medical Center · US

Funding

Airway epithelial cell and lymphocyte interactions in chronic lung allograft dysfunction pathogenesisR01HL161048 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHN GREENLAND, TEREZA MARTINU · 2022 to 2026
$3.3M
The Clinical and Molecular Impacts of Lung Primary Graft DysfunctionU01HL163294 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN GREENLAND, JOHN F MCDYER · 2022 to 2026
$2.2M
Telomere Dysfunction as a cause of Chronic Lung Allograft DysfunctionR01HL151552 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GREENLAND, JOHN · 2020 to 2024
$1.6M
Cytomegalovirus Immune Responses in Chronic Lung Allograft Dysfunction PathogenesisI01CX002011 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI GREENLAND, JOHN · 2020 to 2025
–
Natural killer cells in pulmonary ischemia-reperfusion injuryIK2BX005301 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI Daniel Calabrese · 2021 to 2026
–
BLRD VA IK2 BX005301CSRD VA I01 CX002011NHLBI NIH HHS R01 HL151552NHLBI NIH HHS R01 HL161048NHLBI NIH HHS U01 HL163294
6 · The paper itself

Abstract

backgroundAcute lung allograft dysfunction (ALAD) is an imprecise syndrome denoting concern for the onset of chronic lung allograft dysfunction (CLAD). Mechanistic biomarkers are needed that stratify risk of ALAD progression to CLAD. We hypothesized that single cell investigation of bronchoalveolar lavage (BAL) cells at the time of ALAD would identify immune cells linked to progressive graft dysfunction.

methodsWe prospectively collected BAL from consenting lung transplant recipients for single cell RNA sequencing. ALAD was defined by a ≥10% decrease in FEV

resultsBAL was assessed for 17 ALAD cases with subsequent decline (ALAD declined), 13 ALAD cases that resolved (ALAD recovered), and 15 cases with stable lung function. We observed broad differences in frequencies of the 26 unique cell populations across groups (p = 0.02). A CD8 T cell (p = 0.04) and a macrophage cluster (p = 0.01) best identified ALAD declined from the ALAD recovered and stable groups. This macrophage cluster was distinguished by an anti-inflammatory signature and the CD8 T cell cluster resembled a Tissue Resident Memory subset. Anti-inflammatory macrophages signaled to activated CD8 T cells via class I HLA, fibronectin, and galectin pathways (p < 0.05 for each). Recipients with discordance between these cells had a nearly 5-fold increased risk of severe graft dysfunction or death (HR 4.6, 95% CI 1.1-19.2, adjusted p = 0.03). We validated these key findings in 2 public lung transplant genomic datasets.

conclusionsBAL anti-inflammatory macrophages may protect against CLAD by suppressing CD8 T cells. These populations merit functional and longitudinal assessment in additional cohorts.

Indexed as

CD8-Positive T-LymphocytesDisease ProgressionLung TransplantationMacrophagesAcute DiseaseAdultAllograftsBronchoalveolar Lavage FluidFemaleGraft RejectionHumansMaleMiddle AgedPrimary Graft DysfunctionProspective Studiesacute lung allograft dysfunctionbronchoalveolar lavageCD8 T cellchronic lung allograft dysfunctionlung transplantsingle cell RNA sequencing

Identifiers

PMID38367738
PMCPMC11230518
OpenAlexW4391849559

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.